Oestrogens, Beatson and endocrine therapy

Endocrine-Related Cancer

Volumn 4, Issue 3, 1997, Pages 371-380

  Howell, A ^a   Clarke, R B ^a   Anderson, E ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; FULVESTRANT; GONADORELIN AGONIST; LETROZOLE; TAMOXIFEN; VOROZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; BREAST CANCER; CANCER THERAPY; FEMALE; HISTORY OF MEDICINE; HORMONAL THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RAT; REVIEW;

EID: 0030840728     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040371     Document Type: Review

References (74)

1. Adler L 1912 Zur physiologie und pathologie der ovarialfunktion. Arch f Gynak 86 349.
2. Allegra JC & Lippman ME 1978 Growth of a human breast cancer cell line in serum-free hormone-supplemented medium. Cancer Research 38 3823-3829.
3. Allen E & Doisy EA 1923 An ovarian hormone: preliminary report on its localization, extraction and partial purification and action in test animals. Journal of the American Medical Association 81 819-821.
4. Ascheim S & Zondek B 1927 Hypophysenvorderlappen hormon und ovarialhormon im harm von schwangeben. Klin. Webnschr. (July 9) 1322.
5. Bachmann WE, Cole W & Wilde AL 1939 The total synthesis of the sex hormone Equilenin. Journal of the American Chemical Society 61 974.
6. Beatson GT 1896 On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet ii 104-107.
7. Berry M, Metzger D & Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell type and promoter-context dependent agonist activity of the antioestrogen 4-hydroxytamoxifen. EMBO Journal 9 2811-2818.
8. Berthois Y, Katzenellenbogen JA & Katzenellenbogen BS 1986 Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in tissue culture. Proceedings of the National Academy of Sciences of the USA 83 2496-2500.
9. Burrows H 1935 Carcinoma mammae occurring in the male mouse under continued treatment with oestrin. Americal Journal of Cancer 24 613.
10. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A & Plourde PV 1996 Anastrazole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Journal of Clinical Oncology 14 2000-2011.
11. Cole MP, Jones CTA & Todd IDH 1971 A new antioestrogenic agent in late breast cancer, an early clinical appraisal of ICI 146474. British Journal of Cancer 25 270-275.
12. Coombes RC, Goss P, Dowsett M, Gazet J-C & Brodie A 1984 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet ii 1237-1239.
13. Darbre PD & King RJB 1987 Progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors. Cell 51 521-528.
14. DeCourmelles FV 1922 La radiotherapie indirecte ou dirigee oar les correlation organiques. Archives d'Electricite Medical 32 264.
15. DeSombre ER & Arbogast LY 1974 Effect of the antioestrogen C16294 on the growth of rat mammary tumours. Cancer Research 34 1971-1976.
16. Dickson RB, Huff KK, Spencer EM & Lippman ME 1986 Induction of epidermal growth factor-related peptides by 17β-estradiol in MCF-7 human breast cancer cells. Endocrinology 118 138-142.
17. Dodds EC, Goldberg L, Lawson W & Robinson R 1938 Oestrogenic activity of certain synthetic compounds. Nature 141 247-248.
18. Doisy EA, Veler CD & Thayer S 1929 Folliculin from urine of pregnant women. American Journal of Physiology 90 329-330.
19. Douglas M 1952 The treatment of advanced breast cancer by hormone therapy. British Journal of Cancer 6 32-45.
20. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339 1-15.
21. Fellner OO 1912 Experimentell zeugte wachstumveranderungen am weiblichen genitale der kaninchen. Path. u path Anat 28 673.
22. Folca PJ, Glascock RF & Irvine WT 1961 Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy. Lancet 1795-798.
23. Frank RT & Rosenbloom J 1915 Physiologically active substances contained in the placenta and in the corpus luteum. Surgery Gynaecology and Obstetrics 21 646.
24. Gardner WU, Strong LC & Smith GM 1939 The mammary glands of mature female mice of strains varying in susceptibility to spontaneous tumor development. Americal Journal of Cancer 37510-517.
25. Goormaghtigh N & Amerlinck A 1930 Réalisation expérimentale de la maladie de reclus de la mamelle chez la souris. Bulletin du Cancer 14 527-543.
26. Gottardis MM & Jordan VC 1988 Development of tamoxifen stimulated growth of MCF-7 tumors in athymic nude mice after long term antiestrogen administration. Cancer Research 48 5183-5187.
27. Graham ML, Smith JA, Jewett PB & Horwitz KB 1992 Heterogeneity of progesterone receptor content and remodelling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Research 32 593-602.
28. Griffiths CT, Hall TC, Saba Z et al. 1973 Preliminary trial of aminoglutethimide in breast cancer. Cancer 32 31-37.
29. Haddow A, Watkinson JM & Patterson E 1944 Influence of synthetic oestrogens upon advanced malignant disease. British Medical Journal 2 393-398.
30. Herrmann E 1915 Ueber eine wirksame substang im eierstocke und in der placenta. Monatschr. f Geburtsch u Gynak. 41 1.
31. Horwitz KB, Yoseki Y & Mcguire WL 1978 Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogens. Endocrinology 103 1742-1751.
32. Howell A 1988 Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. Proceedings of the Royal Society of Edinburgh 95B 49-57.
33. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J & Sellwood RÀ 1988 The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. European Journal of Cancer and Clinical Oncology 24 1567-1572.
34. Howell A, Dodwell DJ, Anderson H & Redford J 1992 Response after withdrawal of tamoxifen and progestagens in advanced breast cancer. Annals of Oncology 3 611-617.
35. Howell A, DeFriend DJ, Robertson J, Blarney R & Walton P 1995 Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345 29-30.
36. Howell A, Downey S & Anderson E 1996 New endocrine therapies for breast cancer. European Journal of Cancer 32A 576-589.
37. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME & Dickson RB 1986 Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Research 46 4613-4619.
38. Huggins C 1965 Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Research 25 1163-1167.
39. Huggins C & Dao T 1953 Adrenalectomy and oophorectomy in the treatment of advanced carcinoma of the breast. Journal of the American Medical Association 151 1388-1394.
40. Huggins C, Torralba Y & Mainzer K 1956 Hormonal influences on mammary tumours in the rat. I. Acceleration of growth of transplanted flbroadenoma in ovariectomised and hypophysectomised rats. Journal of Experimental Medicine 104 525-538.
41. Jensen EV, DeSombre ER, Hurst DJ, Kawashima T & Jungblut PW 1967 Estrogen receptor interactions in target tissue. Archives of Anatomy, Microscopy and Morphological Exp 56 547-569.
42. Jordan VC 1976 Effect of tamoxifen (ICI 146,474) on initiation and growth of DMBA-induced rat mammary carcinoma. European Journal of Cancer 12 419-424.
43. Klijn JGM & DeJong FH 1982 Treatment with luteinizing hormone releasing hormone analogue (Buserelin) in premenopausal patients with breast cancer. Lancet i 1213-1216.
44. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R & Dickson RB 1987 Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 417-428.
45. Lacassagne A 1932 Apparition de cancers de la mamelle chez la souris male, soumise a des injections de folliculine. Comptes Rendus de l'Academie des Sciences Series III 195 630-632.
46. Lacassagne A 1934 Sur la pathologenie de l'adenocarcinoma mammaire de la souris. Comptes Rendus des Sciences de la Societé de Biologie et de ses Filailes 115 937-939.
47. Lacassagne A 1938 Statisque des differents cancers constates dans les lignees selectionees de souris, apres action prolongee d'hormones oestrogenes. Bulletin Association Francais Etudes Cancer 27 96-98.
48. Lathrop ABC & Loeb L 1916 Further investigations on the origins of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. Journal of Cancer Research 1 1-19.
49. Legault-Poisson S, Jolivet J & Poisson R 1979 Tamoxifen-induced tumour stimulation and withdrawal response. Cancer Treatment Reports 63 1839-1841.
50. Leung BS, Moseley S, Davenport CE et al. 1975 Estrogen receptor in prediction of clinical responses to endocrine ablation. In Estrogen Receptor in Prediction of Clinical Responses to Endocrine Ablation, pp 107-129. Eds WL McGuire, PP Carbone & EP Vollmer. New York: Raven Press.
51. Lippman M, Bolan G & Huff K 1976 The effects of androgens and antiandrogens on hormone responsive human breast cancer in long term tissue culture. Cancer Research 36 4610-4618.
52. Loeb L 1919 Internal secretions as a factor in the origin of tumours. Journal of Medical Research 40 477-479.
53. Luft R & Olivecrona H 1953 Experiences with hypophysectomy in man. Journal of Neurosurgery 10 301-316.
54. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
55. Millar MJ & Noble RL 1952 Effects of exogenous hormones on growth characteristics and morphology of transplanted mammary fibroadenoma of the rat. British Journal of Cancer 8 495-507.
56. Murray WS 1927 Ovarian secretion and tumor incidence. Science 66 600-601.
57. Nagasawa H & Yanai R 1972 Inhibitory effect of estrogen on mammary growth and its counteraction by pituitary isograft in mice. Endocrinologia Japonica 19 107-110.
58. Nicholson RI & Golder P 1975 The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. European Journal of Cancer 12 711-717.
59. Noble RL & Collip JB 1941 Regression of oestrogen-induced mammary tumours in female rats following removal of the stimulus. Canadian Medical Association Journal 44 1-5.
60. Osborne CK, Coronado EB & Robinson JP 1987 Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. European Journal of Cancer and Clinical Oncology 23 1189-1196.
61. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL & Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 87 746-750.
62. Reddel LL & Sutherland RL 1984 Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. European Journal of Cancer and Clinical Oncology 11 1419-1424.
63. Robertson JF 1996 Oestrogen receptor a stable phenotype in breast cancer. British Journal of Cancer 73 5-12.
64. Schinzinger A 1889 Uber carcinoma mammae. Zent Org Gesamte Chir 29 55-57.
65. Segaloff A & Maxfield WS 1971 The synergism between radiation and estrogen in the production of mammary cancer in the rat. Cancer Research 31 166-168.
66. Sirbasku DA 1978 Estrogen-induction of growth factors specific for hormone-responsive mammary, pituitary and kidney tumor cells. Proceedings of the National Academy of Sciences of the USA 75 3786-3790.
67. Soule HD & McGrath CM 1980 Estrogen-responsive proliferation of clonal human breast cancer cells in athymic mice. Cancer Letters 10 177-189.
68. Soule HD, Vazquez A, Long A, Albert S & Brennan M 1973 A human cell line from a pleural effusion derived from a breast carcinoma. Journal of the National Cancer Institute 51 1409-1413.
69. Ulrich P 1939 Testosterone et son rôle possible dans le traitment de certains cancers du sein. International Union Against Cancer 4 377.
70. Vignon F, Derocq D, Chambon M & Rochefort H 1983 Estrogen-induced proteins secreted by MCF7 human breast cancer cells stimulate their proliferation. Comptes Rendus de l'Academie des Sciences Series III 296 151-156.
71. Walpole AL & Patterson E 1949 Synthetic oestrogens in mammary cancer. Lancet ii 783-786.
72. Westley BR & May FEB 1991 IGFs and control of cell proliferation in breast and other cancers. Reviews on Endocrine-Related Cancer 39 29-34.
73. Woolley G, Fekete E & Little CC 1939 Mammary tumor development in mice ovariectomized at birth. Proceedings of the National Academy of Sciences of the USA 25 277-279.
74. Yanai R & Nagasawa H 1971 Enhancement by pituitary isografts of mammary hyperplastic nodules in adrenoovariectomised mice. Journal of the-National Cancer Institute 46 1251-1255.